相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma
Teri N. Kreisl et al.
NEURO-ONCOLOGY (2011)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome
A. Wick et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Update on molecular findings, management and outcome in low-grade gliomas
T. David Bourne et al.
NATURE REVIEWS NEUROLOGY (2010)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee et al.
NEURO-ONCOLOGY (2010)
Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study
James J. Vredenburgh et al.
ONCOLOGIST (2010)
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
Bevacizumab for Recurrent Alkylator-Refractory Anaplastic Oligodendroglioma
Marc C. Chamberlain et al.
CANCER (2009)
Classification and management of anaplastic gliomas
Wolfgang Wick et al.
CURRENT OPINION IN NEUROLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Eudocia C. Quant et al.
NEURO-ONCOLOGY (2009)
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
S. Taillibert et al.
NEUROLOGY (2009)
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Annick Desjardins et al.
CLINICAL CANCER RESEARCH (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
分享论文
